Abstract
Recent population-based surveys estimate that 1 percent of adolescents in the United States identify as transgender. Gonadotropin-releasing hormone analogs (GnRHa) are commonly prescribed to suppress endogenous puberty for transgender adolescents. There are limited data regarding the mental health benefits of this treatment. The current study evaluated the associations between treatment with pubertal suppression during adolescence and adult mental health outcomes, including measures of suicidality.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
